AVITA Medical (FRA:51KB) Debt-to-Asset : 0.56 (As of Sep. 2024)

View and export this data going back to 2020. Start your Free Trial

What is AVITA Medical Debt-to-Asset?

AVITA Medical's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was €0.00 Mil. AVITA Medical's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was €41.11 Mil. AVITA Medical's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Sep. 2024 was €73.03 Mil. AVITA Medical's debt to asset for the quarter that ended in Sep. 2024 was 0.56.

AVITA Medical Debt-to-Asset Historical Data

The historical data trend for AVITA Medical's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AVITA Medical Debt-to-Asset Chart

AVITA Medical Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.02

0.01

0.38

AVITA Medical Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Debt-to-Asset	Get a 7-Day Free Trial															0.03	0.38	0.46	0.51	0.56

Competitive Comparison of AVITA Medical's Debt-to-Asset

For the Medical Devices subindustry, AVITA Medical's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AVITA Medical's Debt-to-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, AVITA Medical's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where AVITA Medical's Debt-to-Asset falls into.

AVITA Medical Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

AVITA Medical's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.821	+	38.068)	/	102.374
	=	0.38

AVITA Medical's Debt-to-Asset for the quarter that ended in Sep. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	41.109)	/	73.027
	=	0.56

AVITA Medical (FRA:51KB) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

AVITA Medical Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of AVITA Medical's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

AVITA Medical Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » AVITA Medical Inc (FRA:51KB) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

RCEL:USA AVHHL:USA 51KA:Germany AVH:Australia

Address

28159 Avenue Stanford, Suite 220, Valencia, Los Angeles, CA, USA, 91355

Website

https://www.avitamedical.com

Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the US with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.

AVITA Medical Headlines

No Headlines